Last reviewed · How we verify
rhubarb
Rhubarb, marketed by Fudan University, holds a unique position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the lack of direct competitors. However, the primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | rhubarb |
|---|---|
| Sponsor | Fudan University |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients (PHASE2)
- Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. (PHASE2)
- Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure (PHASE4)
- Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents (EARLY_PHASE1)
- A Study of Herbal Supplements in Cancer Survivors With Constipation (NA)
- Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis (EARLY_PHASE1)
- YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2 (NA)
- YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |